Yale joins B-MS' International Immuno-Oncology Network

Bristol-Myers Squibb (NYSE: BMY) today announced that the Yale Cancer Center has joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between B-MS and academia that aims to advance translational immuno-oncology (I-O) science.

Formed in 2012 by the US pharma major, the II-ON was one of the first networks to bring academia and industry together to further the scientific understanding of I-O, and has since expanded from 10 to 16 sites across North America, Europe, Japan and Australia. Today, the partners collaborate to generate innovative I-O science, launch biology-driven trials and apply cutting-edge technologies with the goal of translating research findings into clinical trials and, ultimately, supporting efforts to improve survival outcomes across tumor types.

“The II-ON gives us the chance to work more efficiently and collaboratively with Bristol-Myers Squibb and the other II-ON academic centers to address scientific questions in I-O,” said Roy Herbst, director of the Center of Immuno-Oncology at Yale Cancer Center and Yale’s principal investigator of the II-ON team. “The hope is this early research can someday inform clinical trials and ultimately help us to achieve our goal of transforming the way we treat people affected by cancer,” Dr Herbst added.